212 related articles for article (PubMed ID: 23180965)
1. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study.
Alam S; Khan ZI; Mustafa G; Kumar M; Islam F; Bhatnagar A; Ahmad FJ
Int J Nanomedicine; 2012; 7():5705-18. PubMed ID: 23180965
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterisation of PEG modified chitosan nanocapsules loaded with thymoquinone.
Vignesh Kumar SK; Renuka Devi P; Harish S; Hemananthan E
IET Nanobiotechnol; 2017 Feb; 11(1):104-112. PubMed ID: 28476970
[TBL] [Abstract][Full Text] [Related]
3. Development and biological evaluation of protective effect of kidney targeted N-acetylated chitosan nanoparticles containing thymoquinone for the treatment of DNA damage in cyclophosphamide-induced haemorrhagic cystitis.
Prajapati C; Agrawal YO; Agnihotri VV; Mahajan UB; Patil KR; Patil DD; Patil CR
Int J Biol Macromol; 2022 Aug; 214():391-401. PubMed ID: 35714868
[TBL] [Abstract][Full Text] [Related]
4. Rutin-encapsulated chitosan nanoparticles targeted to the brain in the treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Naqvi AA; Alam MA; Ashafaq M; Samim M; Iqbal Z; Ahmad FJ
Int J Biol Macromol; 2016 Oct; 91():640-55. PubMed ID: 27264648
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
[TBL] [Abstract][Full Text] [Related]
6. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501
[TBL] [Abstract][Full Text] [Related]
7. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
8. Thymoquinone-encapsulated chitosan nanoparticles coated with polysorbate 80 as a novel treatment agent in a reserpine-induced depression animal model.
Fahmy HM; Khadrawy YA; Abd-El Daim TM; Elfeky AS; Abd Rabo AA; Mustafa AB; Mostafa IT
Physiol Behav; 2020 Aug; 222():112934. PubMed ID: 32353367
[TBL] [Abstract][Full Text] [Related]
9. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
10. Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release.
Shahein SA; Aboul-Enein AM; Higazy IM; Abou-Elella F; Lojkowski W; Ahmed ER; Mousa SA; AbouAitah K
Int J Nanomedicine; 2019; 14():5503-5526. PubMed ID: 31410001
[TBL] [Abstract][Full Text] [Related]
11. The nasal delivery of nanoencapsulated statins - an approach for brain delivery.
Clementino A; Batger M; Garrastazu G; Pozzoli M; Del Favero E; Rondelli V; Gutfilen B; Barboza T; Sukkar MB; Souza SA; Cantù L; Sonvico F
Int J Nanomedicine; 2016; 11():6575-6590. PubMed ID: 27994459
[TBL] [Abstract][Full Text] [Related]
12. Intranasal delivery of tapentadol hydrochloride-loaded chitosan nanoparticles: formulation, characterisation and its in vivo evaluation.
Javia A; Thakkar H
J Microencapsul; 2017 Nov; 34(7):644-658. PubMed ID: 28862072
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Neuroprotective Effect of Thymoquinone Nanoformulation in the Rodent Cerebral Ischemia-Reperfusion Model.
Xiao XY; Zhu YX; Bu JY; Li GW; Zhou JH; Zhou SP
Biomed Res Int; 2016; 2016():2571060. PubMed ID: 27725936
[TBL] [Abstract][Full Text] [Related]
14. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
15. Preparation of Chitosan Okra Nanoparticles: Optimization and Evaluation as Mucoadhesive Drug Delivery System.
Brar V; Kaur G
Pharm Nanotechnol; 2018; 6(3):180-191. PubMed ID: 30101724
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic significance of thymoquinone-loaded chitosan nanoparticles on streptozotocin/nicotinamide-induced diabetic rats: In vitro and in vivo functional analysis.
Hosni A; Abdel-Moneim A; Hussien M; Zanaty MI; Eldin ZE; El-Shahawy AAG
Int J Biol Macromol; 2022 Nov; 221():1415-1427. PubMed ID: 36096255
[TBL] [Abstract][Full Text] [Related]
17. Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: In vivo study.
Fahmy HM; Fathy MM; Abd-Elbadia RA; Elshemey WM
Life Sci; 2019 Apr; 222():94-102. PubMed ID: 30826496
[TBL] [Abstract][Full Text] [Related]
18. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
19. Serratiopeptidase loaded chitosan nanoparticles by polyelectrolyte complexation: in vitro and in vivo evaluation.
Mali N; Wavikar P; Vavia P
AAPS PharmSciTech; 2015 Feb; 16(1):59-66. PubMed ID: 25171974
[TBL] [Abstract][Full Text] [Related]
20. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
